Parkinson's disease is primarily associated with a significant decline in dopamine levels within the brain. This crucial neurotransmitter is essential for regulating movement, memory, mood, and various other vital functions. As dopamine-producing neurons deteriorate, individuals experience a loss of motor control, leading to characteristic symptoms such as tremors, rigidity, and slowed movements.
In a groundbreaking initiative, researchers at Keck Medicine of USC are exploring a novel treatment aimed at directly counteracting this dopamine deficiency. As part of an early-stage clinical trial, physicians are implanting specially engineered stem cells into the brains of patients. These innovative cells are designed to replace damaged neurons and stimulate dopamine production.
"Restoring normal dopamine levels in the brain could slow the progression of Parkinson's disease and improve motor functions," stated Dr. Brian Lee, a neurosurgeon at Keck Medicine and the principal investigator of the study.
Revolutionizing Treatment with Induced Pluripotent Stem Cells
The therapy utilizes a cutting-edge form of stem cell known as induced pluripotent stem cells (iPSCs). Unlike traditional embryonic stem cells, iPSCs are derived from adult cells (such as skin or blood) that are reprogrammed to revert to a pluripotent state. This allows them to differentiate into various cell types within the body.
"We are confident that these iPSCs can effectively mature into dopamine-producing neurons, providing a promising avenue for revitalizing dopamine production in the brain," explained Dr. Xenos Mason, a neurologist specializing in movement disorders and co-principal investigator of the study.
Precision Delivery and Ongoing Observation
The implantation procedure involves creating a small opening in the skull to access the brain. Dr. Lee employs magnetic resonance imaging (MRI) to accurately position the stem cells within the basal ganglia, the area responsible for movement coordination.
Following the surgery, participants will be monitored for 12 to 15 months to assess symptom changes and identify any potential side effects, such as dyskinesia (excessive movements) or infection. Researchers plan to track patients' progress for up to five years.
"Our ultimate objective is to develop a method that can restore motor function and enhance the quality of life for patients," Dr. Lee added.
Keck Medicine is one of three clinical trial sites in the United States, which includes 12 individuals with moderate to severe Parkinson's disease.
The stem cell treatment, designated RNDP-001, is being developed by Kenai Therapeutics, a biotechnology firm dedicated to advancing therapies for neurological conditions. The U.S. Food and Drug Administration has granted the Phase 1 REPLACE™ trial fast-track designation to expedite its development and review.